The lung cancer targeted drug Platinib belongs to which generation of drugs

Pralsetinib is a targeted therapy for lung cancer targeting RET gene fusion mutations. It is the third generation of targeted drugs. Its emergence fills the gap in the treatment of RET-positive non-small cell lung cancer in the past and provides more targeted treatment options for such patients. RETGene fusion is not common in lung cancer, accounting for only 1-2% of non-small cell lung cancer. However, for these patients, platinib is a landmark precision treatment.

Platinib was originally designed to enhance the inhibitory activity against RET fusion genes while reducing non-specific effects on other kinases, thereby reducing side effects. Compared with traditional chemotherapy or early targeted drugs, platinib has demonstrated higher response rates and longer progression-free survival in clinical studies. Especially in patients who have already received other treatment options but failed to respond well, Platinib has also shown good efficacy.

It is worth mentioning that platinib is not only effective in RET fusion-positive non-small cell lung cancer, but is also approved for the treatment of RET mutated thyroid cancer. This shows its potential for broad application in multiple RET-driven tumors. Its mechanism of action is based on potent and selective inhibition of RET kinase, thereby blocking the growth signals of cancer cells and achieving the purpose of inhibiting tumor growth.

Currently, platinib has been approved for marketing by the USFDA abroad and has been included in corresponding treatment guidelines. In my country, Platinib has also been approved for marketing, bringing new treatment opportunities to patients with RET fusion-positive lung cancer. With the development of precision medicine, highly selective targeted drugs such as platinib will play an increasingly important role in clinical practice, promoting the treatment of lung cancer in a more personalized and efficient direction.

Reference materials:https://gavreto.com/